- Home
- GNL vs DNLI Comparison
GNL vs DNLI Comparison
Compare GNL & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNL
- DNLI
- Stock Information
- Founded
- GNL 2011
- DNLI 2013
- Country
- GNL United States
- DNLI United States
- Employees
- GNL 73
- DNLI N/A
- Industry
- GNL Real Estate Investment Trusts
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GNL Real Estate
- DNLI Health Care
- Exchange
- GNL Nasdaq
- DNLI Nasdaq
- Market Cap
- GNL 1.7B
- DNLI 1.9B
- IPO Year
- GNL N/A
- DNLI 2017
- Fundamental
- Price
- GNL $7.76
- DNLI $13.24
- Analyst Decision
- GNL Buy
- DNLI Strong Buy
- Analyst Count
- GNL 4
- DNLI 15
- Target Price
- GNL $9.50
- DNLI $33.85
- AVG Volume (30 Days)
- GNL 1.5M
- DNLI 1.3M
- Earning Date
- GNL 05-07-2025
- DNLI 05-06-2025
- Dividend Yield
- GNL 13.08%
- DNLI N/A
- EPS Growth
- GNL N/A
- DNLI N/A
- EPS
- GNL N/A
- DNLI N/A
- Revenue
- GNL $789,545,000.00
- DNLI N/A
- Revenue This Year
- GNL N/A
- DNLI N/A
- Revenue Next Year
- GNL N/A
- DNLI $256.73
- P/E Ratio
- GNL N/A
- DNLI N/A
- Revenue Growth
- GNL 38.85
- DNLI N/A
- 52 Week Low
- GNL $6.51
- DNLI $10.57
- 52 Week High
- GNL $9.11
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- GNL 51.02
- DNLI 41.80
- Support Level
- GNL $7.48
- DNLI $12.86
- Resistance Level
- GNL $7.95
- DNLI $13.77
- Average True Range (ATR)
- GNL 0.15
- DNLI 0.75
- MACD
- GNL -0.01
- DNLI -0.11
- Stochastic Oscillator
- GNL 40.15
- DNLI 14.07
About GNL Global Net Lease Inc.
Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operating, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution; Multi-Tenant Retail; Single-Tenant Retail; and office. The company derives maximum revenue from industrial and distribution segment. The company geographically operates in Unites States, United Kingdom, Canada and Europe.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.